Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02414945
Other study ID # TILs-003-Meso
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 15, 2015
Est. completion date October 2020

Study information

Verified date January 2023
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung). Patients will receive an infusion (given by vein) of autologous tumor infiltrating lymphocytes (TILs). TILs are a type of white blood cells that recognizes tumor cells and enter them which causes the tumor cells to break down. Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and fludarabine to prepare the body to receive the TILs. After cell infusion, patients will receive low-dose interleukin-2 therapy. This study will see how safe and useful this regimen is in treating malignant pleural mesothelioma.


Description:

The investigational infusion product consists of autologous, in vitro-expanded tumor-infiltrating lymphocytes (TILs). The target number of cells for infusion is between 1 x 1010 and 1.6 x 1011. The cells are given intravenously over a 20-30 minute infusion. Prior to infusion of TILs, patients will receive a preparative regimen of cyclophosphamide (60 mg/kg/day x 2 days intravenously) and fludarabine (25 mg/m2/day x 5 days intravenously). After the cell infusion, patients will receive low-dose interleukin-2 (IL-2) therapy (125,000 IU/kg/day subcutaneously for 2 weeks with a 2 day break between each week. The goal for the total number of doses is 9-10). Because confusion is a possible side effect of IL-2 administration, a Durable Power of Attorney will be signed by the patient to identify a surrogate to make decisions if a patient becomes unable to make decisions.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date October 2020
Est. primary completion date October 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Able to sign and date the informed consent form. - Must have measurable stage I-IV malignant pleural mesothelioma at the time of investigational treatment. - May have 3 or fewer asymptomatic brain metastases. - Patient age: = 18 years. - Clinical performance status of ECOG 0 or 1. - Life expectancy > 3 months from the date of consent. - Laboratory analyses of tumor-infiltrating lymphocytes (TILs) from the patient must demonstrate that the TILs are suitable for use in protocol treatment - More than 30 days has elapsed since any prior systemic therapy at the time of the cell infusion, or more than six weeks since prior nitrosurea therapy. All toxicities must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less - Adequate organ function - Women of child-bearing potential must have a negative pregnancy test. Patients of both genders must be willing to practice birth control during treatment and for 6 months post completion of IL-2 treatment. - Patients must have adequate respiratory function in the opinion of the treating thoracic physician Exclusion Criteria: - Ongoing or prior use systemic steroid therapy within 4 weeks before the TILs infusion will be excluded. - Known HIV positive patients will be excluded. - Active hepatitis B or hepatitis C, syphilis, or HTLV will be excluded. - Must not have any active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, uncontrolled psychiatric disorders, or other conditions that may affect compliance with the trial. - Must have no active underlying cardiac illnesses defined by positive stress test, LVEF <40% or ongoing life threatening arrhythmias.

Study Design


Intervention

Drug:
Cyclophosphamide

Fludarabine

Biological:
Autologous tumor infiltrating lymphocytes (TILs)

Interleukin-2


Locations

Country Name City State
Canada Princess Margaret Cancer Centre Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of adverse events for each event reported and the severity and attribution to study therapy of each event To determine the feasibility and safety of chemotherapy in combination with infusion of tumor-infiltrating lymphocytes followed by low-dose interleukin-2 in patients with malignant pleural mesothelioma. 5 years
Secondary Percentage of patients with a clinical response to the study treatment 5 years
See also
  Status Clinical Trial Phase
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Active, not recruiting NCT04914897 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) Phase 2
Recruiting NCT05910112 - Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
Recruiting NCT02588131 - A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Phase 2
Recruiting NCT05930665 - Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma Phase 2
Recruiting NCT06362369 - A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Phase 1/Phase 2
Recruiting NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02585362 - Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program N/A
Completed NCT00299962 - Gene Therapy for Pleural Malignancies Phase 1
Terminated NCT04106973 - Mesothelioma Early Detection by VOCs
Not yet recruiting NCT06155279 - Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Phase 2
Not yet recruiting NCT06416930 - Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma Phase 2
Completed NCT01160458 - Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Phase 2
Completed NCT02899195 - Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Phase 2
Active, not recruiting NCT04040231 - Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Phase 1
Completed NCT04324437 - eRAPID: Online Symptom Reporting in Lung Cancer N/A
Completed NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Phase 1
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Terminated NCT00895648 - Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma Phase 2
Completed NCT00165516 - Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Phase 2